Dr Mosima Mabunda

Chief Clinical Officer @Vitality_SA | Health & Wellness #Digital Health # Lifestyle Medicine

[Tennis Canada @TennisCanada]

Left it all out on court 🫶

A tremendous effort from Félix Auger-Aliassime 🇨🇦, who gave it everything in a remarkable battle before narrowly falling to seven-time Wimbledon champion Novak Djokovic 🇷🇸 in a fifth-set super tiebreak.

Read more 👉 https://t.co/SHK3AWfV0t

[Wimbledon @Wimbledon]

Our first semi-finalist. Her first semi-final.

Coco Gauff advances to a maiden final four at The Championships 👏

#Wimbledon

[JACC Journals @JACCJournals]

The AHA/ACC/ADA/ASN have developed the first-ever guideline aimed at preventing & managing #CKM syndrome, an interconnected set of health conditions that significantly 📈 the risk of multiorgan complications & negative CV outcomes https://t.co/kmUw3woToN #JACC #ClinicalGuidelines

[AHA Science @AHAScience]

Published today, the first-ever clinical practice guideline on cardiovascular-kidney-metabolic syndrome from the American Heart Association and @ACCinTouch.

Cardiovascular-kidney-metabolic (CKM) syndrome staging is recommended for youths and adults to prevent CKM syndrome stage progression, to tailor therapy to absolute risk, to reduce cardiovascular events and loss of kidney function across the life course, and to promote CKM syndrome stage regression through lifestyle changes and weight loss.

The diagnosis of CKM syndrome stage requires assessment of metabolic health, kidney function, and cardiovascular risk factors, which enhances the identification of frequently unrecognized or asymptomatic CKM conditions.

✍🏼 @ChiadiNdumele @HeartDocSadiya @kardiologykazi @noshreza @virani_md @biykemb @NutritionHF @mandeepbajaj65 @KatherineTuttl8 @RangaswJ @lisaVWMD @KBreathettMD @EmoryFamMed @ShoaClarke @mad_sters @jmortonmd @sripalbangalore @AnumSaeedMD

[Eric Topol @EricTopol]

The suppressed report that concluded there is no protective or safe level of alcohol consumption, now published. It was commissioned by US Congress
Report https://t.co/XmmsSo9q3q
Editorial https://t.co/8NuqBwkugM
"Despite the study’s adherence to its mandate, its findings were sidelined.”

[Roland-Garros @rolandgarros]

🐶🏆

#RolandGarros

[The Economist @TheEconomist]

Nearly half of all Americans and around 40% of Britons now use a device to track their sleep. Are these gadgets accurate—and do their users get a better night’s rest? https://t.co/oCv9SHZ5bT

Illustration: Cristina Spanò

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Worldwide, approximately half of the general population is actively attempting to lose weight. However, weight loss is typically followed by substantial weight regain, often leading to repeated cycles of loss and gain of bodyweight https://t.co/6vqmVu0nfO
#obesity #weightloss

[Eric Topol @EricTopol]

Love the lede😉
"The newest luxury condominium amenity for wealthy New Yorkers isn’t a rooftop pool, private dining room or celebrity-chef restaurant. It is a whole-body MRI."
https://t.co/4jLv1oWi2i

[Eric Topol @EricTopol]

What's the right amount of time for resistance training?
A new study supports 90-120 minutes/week across multiple outcomes, which plateaus beyond that for lack of additional benefit
From 30-year follow-up of ~150,000 participants
https://t.co/mUy9o4HkbH

[Tony Fadell @tfadell]

Nobel Prize winning economist Kenneth Arrow wrote about "learning by doing" decades ago. He knew that productivity and expertise improve through experience.

The messy, repetitive works is often where you learn the patterns that eventually become judgment. Knowledge can be taught, but judgement is built through lived experience.

The first draft you rewrite. The customer call you listen to. The bug you fix and fix again. The factory floor you walk.

Small decisions you make every day teach you judgement. And, judgement is the thing everyone wants from senior people in the workplace. If we automate away every entry-level task without replacing the learning loop, we are removing a part of the process that creates experts.

The goal should be to use AI to accelerate learning, remove friction, and give people better tools to build expertise faster.

https://t.co/MpFZzCk1An

Thanks @Fortune & @tbove4 for sharing this story. Link in the comments.

[AHA Science @AHAScience]

Published today, The Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement from the American Heart Association.

Because clinicians and health professionals play a pivotal role in fostering and sustaining patients’ health goals, this scientific statement provides an overview of evidence-based strategies for targeted weight loss counseling and for leveraging digital technology, particularly to engage patients and achieve realistic physical activity goals.

@DrGermanMD

📷 Practical application of physical activity for weight loss and weight loss maintenance.

[EHJ Editor-in-Chief @ehj_ed]

The best treatment for heart failure? Preventing it. New ESC scientific statement brings together HFA, EAPC, ACNAP & the Council on Hypertension to define the future of heart failure prevention. Read more in #EHJ.
https://t.co/PnoCKxUDbW
#HF #cardiotwitter @ESC_Journals @escardio

[Discovery Vitality @Vitality_SA]

Your future sleep will thank you. Your bedroom might too.

Small actions now = better sleep later.

Complete your Vitality Health Check and activate Vitality Sleep Rewards between 15 May and 30 June 2026 for a chance to win a bedroom makeover valued at Đ500,000 (R50,000).

[SAHPRA @SAHPRA1]

🔬 What are “peptides”?

Think of them as tiny building blocks your body uses to make proteins — helping to construct and repair different parts of your body.

They occur naturally in the body and play an important role in functions like hormones, healing, and communication between cells.

Some products made from these building blocks are being marketed for weight loss, muscle building, anti-ageing and performance enhancement. However, not all of these products are registered or tested for safety.

⚠️ Always be cautious and speak to a healthcare professional before using any of these products.

For more information, visit https://t.co/1uWK33peQM

#HealthAwareness #MedicineSafety #SAHPRA

[Eric Topol @EricTopol]

Insightful, as always, @DrHelenOuyang
gift link https://t.co/tXPeZ1Dq75

[JAMA @JAMA_current]

💡 JAMA Insights: #GLP1 receptor agonists and dual incretin agents support weight loss with minimal lifestyle counseling, but diet and activity advice remain necessary for safety and long-term success in #Obesity care.

https://t.co/pFK8LgavVl

[SAHPRA @SAHPRA1]

⚠️ Public Safety Alert: Unregistered Weight-Loss Medicines Seized ⚠️

The South African Health Products Regulatory Authority (SAHPRA), working with the South African Pharmacy Council (SAPC), has taken strong action against the unlawful manufacture and distribution of unregistered GLP-1 medicines used for weight loss.

An inspection at a facility in Pretoria uncovered serious violations, including:
👉️ Illegal large-scale manufacturing under the guise of “compounding”
👉️ Use of untested and illegally imported active ingredients
👉️ Poor sterile conditions and lack of quality controls
👉️ No systems in place to monitor adverse reactions

Several injectable products, including those containing semaglutide and tirzepatide, have been seized, and a full product recall has been initiated. Reports of adverse events, including hospitalisations, have also been noted.

🚫 The use, sale, or promotion of unregistered medicines is illegal and poses a serious risk to public health.

✅ Members of the public are advised to consult qualified healthcare professionals for safe and approved treatment options.

🔗 Find out more: https://t.co/HtOU6E5znS

#SAHPRA #PublicSafety #Healthcare #PatientSafety #Regulation

[Roland-Garros @rolandgarros]

The time has come... ⌛️

#RolandGarros

[Yusuf Abramjee @Abramjee]

The South African Health Products Regulatory Authority and the South African Pharmacy Council have intensified action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines used for weight loss and diabetes treatment.

The crackdown follows a joint investigation and inspection conducted on 11 May 2026 at iDexis (Pty) Ltd in Silverton, Pretoria.

During the operation, authorities seized all injectable GLP-1/GIP products found at the facility, including products containing semaglutide, tirzepatide, and combination formulations.

According to SAHPRA and SAPC, the company was allegedly producing and supplying these medicines under the pretext of “compounding”, but outside the legal framework allowed under South African law.

Compounding is only permitted for preparing medicine for an individual patient based on a valid prescription and cannot be used for large-scale manufacturing, advertising, or commercial distribution.

Investigators uncovered serious regulatory and safety concerns at the facility.

Findings included the alleged illegal importation of semaglutide and tirzepatide active pharmaceutical ingredients (APIs), lack of analytical testing to confirm the medicines’ identity, potency and purity, poor sterile manufacturing conditions, contamination risks, inadequate equipment for aseptic preparation, and the absence of a proper HVAC system required for safe pharmaceutical production.

Authorities also found that the room used to manufacture the GLP-1/GIP products did not meet the standards required for sterile injectable medicines.

In addition, no pharmacovigilance system was in place to monitor or respond to adverse drug reactions.

SAHPRA said it has already received reports of adverse events, including hospitalisations, linked to the use of these products.

As part of the enforcement action, SAHPRA ordered the seizure of all finished products found on site and instructed the company to conduct a full recall of affected medicines distributed through pharmacies, healthcare providers, and other channels.

SAHPRA CEO Dr Boitumelo Semete-Makokotlela warned that unlawful manufacturing, importation, advertising, and distribution of unregistered medicines pose a serious threat to public health and said the regulator would continue taking decisive action against entities violating the Medicines and Related Substances Act.

SAPC CEO Vincent Tlala said pharmacists and pharmacy support staff involved in the unlawful sale, compounding, or distribution of unregistered GLP-1 medicines could face severe disciplinary action, including possible removal from the professional register.

Members of the public have been urged to consult qualified healthcare professionals for advice on weight management and diabetes treatment, and to report any suspicious medicines or adverse reactions to SAHPRA.